TIER: A Phase I/II Study of Thiotepa, Ifosphamide, Etoposide and Rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma

Trial Overview and Summary

This study is looking at a new combination of cancer drugs for primary central nervous system lymphoma (called CNS lymphoma for short). It is a cancer of the lymphatic system that starts in the brain or spinal cord.

Doctors often treat CNS lymphoma with chemotherapy. Sometimes the lymphoma does not respond to chemotherapy or it comes back after treatment. In this situation there is no standard treatment.

In this trial are looking at giving a new combination of the following cancer drugs

  • Thiotepa
  • Ifosphamide
  • Etoposide
  • Rituximab


Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator:  Dr Christopher Fox
Sponsor:  University of Birmingham
Funders:  Bloodwise
Disease Site:  Primary Central Nervous System Lymphoma
Trial Type:  Phase I/II
Status:  Open
UKCRN Study ID: (if applicable)  17668
Open to new sites?  Yes
Recruitment start date:  Feb 2015
Anticipated Recruitment end date  Feb 2018
CRCTU Trial Management Team:  Haematology Team
Trial E-mail Address:  TIER@trials.bham.ac.uk

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More Information

CancerHelp (Cancer Research UK) - TIER trial